"Neurology is experiencing a convergence of multiple enabling technologies: biomarkers that allow early intervention before irreversible damage." More enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, and neuroscience: https://lnkd.in/gwz3jBd7 #Innovation #neuroscience #earlyintervention
Amprion
Biotechnology
San Francisco, California 2,404 followers
The Leader in Alpha-Synuclein SAA Diagnostics for Neurodegenerative Disorders
About us
Amprion is a global leader advancing precision medicine for neurodegenerative disorders through seed amplification testing. Amprion’s SAAmplify™-ɑSYN (formerly SYNTap®) Biomarker Test is a first-in-class, qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies (by detecting pathogenic ɑ-synuclein) such as Parkinson’s disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer’s disease (AD) with Lewy body variant.
- Website
-
https://ampriondx.com
External link for Amprion
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- San Francisco, California
- Type
- Privately Held
- Founded
- 2007
- Specialties
- abeta, tau, neurology, healthcare, Early detection of Parkinson's Disease, Lewy body dementia, Alzheimer's disease, neurodegenerative disorders, alpha-synuclein, synucleinopathies, Lewy body copathology, seed amplification assay, SAA, and precision brain diagnostics
Locations
-
Primary
Get directions
149 New Montgomery St
4fl
San Francisco, California 94105, US
Employees at Amprion
Updates
-
Clinical trials fail when the biology is wrong. Biomarker‑based testing is helping identify who actually has the disease pathology—and who’s most likely to benefit from early‑stage therapies. Read more: https://lnkd.in/g_72r_qD #ClinicalTrials #DrugDevelopment #Neuroscience
-
2025 saw growing recognition of the limitations of symptom-based diagnosis in neurodegeneration. As we move into 2026, integrating pathology-based tools like CSF α‑synuclein seed amplification testing into routine practice can help clinicians deliver more precise, personalized care, especially in complex or ambiguous cases. Learn more: https://lnkd.in/gN9sYsRb. #ClinicalReflection #Neurodiagnostics #2026Outlook #PrecisionMedicine
-
APOE ε4 heterozygotes + LBP increase CAA risk = ε4 homozygotes without LBP. Detecting α-synuclein aggregates via α-synuclein SAA may be key to therapeutic decisions that minimize ARIA risk. Learn more: https://lnkd.in/gUjDACkS. #DementiaCare #Alzheimers #Neurobiology #PrecisionMedicine
-
First report: patients with APOE ε4 + LBP show higher CAA burden at autopsy. Ignoring LBP may underestimate ARIA risk. α-synuclein aggregate testing can refine decisions. Learn more: https://lnkd.in/dSCyYDi6 #AlzheimersDisease #Neurodegeneration #APOE4 #Synuclein
-
Patients with neurodegenerative conditions often experience multiple diagnostic revisions over time. This “diagnostic drift” reflects the limitations of symptom-based assessments. Incorporating α‑synuclein seed amplification testing into clinical workups can reduce uncertainty and provide a stable biological anchor for diagnosis—especially in cases with overlapping features like MCI, RBD, or atypical parkinsonism. Learn more: https://lnkd.in/gN9sYsRb. #NeurologyPractice #BiomarkerTesting #ClinicalDecisionSupport
-
Great interview with Amprion CEO, Dr. Russ Lebovitz, on Diagnosing Dx with David Filby.
The 20-Year Head Start: How Amprion Is Transforming Neurodiagnostics - Dr. Russ Lebovitz, CEO In this episode, Dr. Russ Lebovitz, CEO of Amprion, explains why detecting misfolded proteins years before symptoms begin could completely reshape how we diagnose Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. He breaks down how early detection unlocks new possibilities for intervention, why alpha-synuclein is such a powerful biomarker, and what it really takes to commercialise a diagnostic platform in one of the toughest areas of biotech. 🔥Key Takeaways: 🔹Early detection is essential for slowing neurodegenerative diseases 🔹Misfolded proteins can appear up to 20 years pre-symptom 🔹Diagnostics commercialisation requires deep regulatory expertise 🔹Partnerships like Amprion’s with Mayo Clinic accelerate scaling 🎧 Listen/watch now on: 🔹 YouTube: https://lnkd.in/eKd7pQ_9 🔹 Spotify: https://lnkd.in/eCPK8CdP 🔹 Apple: https://lnkd.in/eR-4gBc4 🔔 If you want to be alerted of new Diagnosing Dx episodes straight to your email inbox sign up here: https://lnkd.in/eQ4cebZv
-
New read in THE PATHOLOGIST: "Inside the Race to Detect Neurodegenerative Disease Early", a conversation with Russ Lebovitz, CEO of Amprion: https://lnkd.in/gjpEN2JA #SAA #NeurodegenerativeDiagnostics #
-
-
Amprion reposted this
Neurodegenerative diseases like Parkinson’s, Lewy body dementia, and Alzheimer’s present significant diagnostic challenges, often leading to delayed or inaccurate diagnoses. In a recent webinar, Matt Binnicker, Ph.D., chief scientific officer for Mayo Clinic Laboratories, and Stuart McCarter, M.D., assistant professor of neurology at Mayo Clinic, discussed how SAAmplify™-αSYN testing, offered through Mayo Clinic Laboratories in collaboration with Amprion, is enhancing diagnostic options for these conditions.
-
Clinical symptoms alone often fail to reflect the underlying pathology in neurodegenerative diseases. Studies show that up to 30% of patients diagnosed with Parkinson’s or DLB lack Lewy body pathology at autopsy. This discrepancy underscores the need for biologically grounded diagnostics. CSF-based α‑synuclein seed amplification testing offers a direct measure of pathology, helping clinicians refine differential diagnoses and reduce reliance on symptom clusters alone. Learn more: https://lnkd.in/gN9sYsRb #ClinicalNeurology #Neurodegeneration #AlphaSynuclein #DiagnosticAccuracy